Stephen K. Brannan, Chief Medical Officer at Karuna Therapeutics, Inc. (KRTX), sold 19,901 shares at $200.11 ($4.0M) on 2023-12-08, disclosed to the SEC on 2023-12-12.
Scheduled sale ($4.0M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $200.11 | 1,565 | $313K | 7.8% |
| 2 | $200.11 | 1,565 | $313K | 7.8% |
| 3 | $201.73 | 2,116 | $427K | 10.6% |
| 4 | $201.73 | 2,116 | $427K | 10.6% |
| 5 | $202.74 | 3,969 | $805K | 20.0% |
| 6 | $202.74 | 3,969 |
| $805K |
| 20.0% |
| 7 | $203.80 | 2,251 | $459K | 11.4% |
| 8 | $203.80 | 2,251 | $459K | 11.4% |
| 9 | $204.18 | 99 | $20K | 0.5% |
| Total | $202.36 avg | 19,901 | $4.0M | 100% |
| Filing → |
| KRTX | SELL | 2024-02-12 | $3.2M | — | Filing → |
| KRTX | SELL | 2024-01-09 | $4.8M | — | Filing → |
| KRTX | SELL | 2023-11-13 | $1.7M | — | Filing → |